UPDATE : Monday, June 18, 2018
상단여백
Venture capital investment in biomedical sector drops 20% in 2017 by Nam Doo-hyun 2018-01-04 09:30
Samyang Biopharm wins patent suit against Helsinn Healthcare by Lee Han-soo 2018-01-03 16:58
70% of biotech firms enjoy stock price gains in 2017 by Nam Doo-hyun 2018-01-02 17:42
HanAll vice chairman sells off stake despite export deal by So Jae-hyeon 2018-01-02 13:57
Kolon Life Science’s shares plummet on drifting export deal by Nam Doo-hyun 2017-12-21 13:16
라인
HanAll inks $30 million tech export deal by So Jae-hyeon 2017-12-20 15:49
₩500-billion Invossa technology export to Japan in peril by Nam Doo-hyun 2017-12-20 14:59
FDA to review Samsung Bioepis’ trastuzumab biosimilar by Lee Han-soo 2017-12-20 14:37
Nature Cell expects to receive conditional approval for Jointstem by Lee Han-soo 2017-12-19 18:22
‘Celltrion’s annual revenue to top ₩3 trillion in 5 years’ by Nam Doo-hyun 2017-12-18 15:55
라인
Samsung Bioepis, Daewoong sign exclusive supply contract for Samfenet by Lee Han-soo 2017-12-18 10:59
Corestem’s NeuroNata-R marks increase in foreign patients by Lee Han-soo 2017-12-15 16:22
FDA approves Pfizer’s Remicade biosimilar by Lee Han-soo 2017-12-14 17:16
Samsung BioLogics’ 2nd factory gets European approval by Lee Han-soo 2017-12-14 10:52
‘Surge of gene-therapy providing hospitals to benefit Invossa’ by Nam Doo-hyun 2017-12-12 15:59
라인
PCL shares rise despite regulator’s warning by Nam Doo-hyun 2017-12-12 11:02
Oscotec shares rebound on launch of US clinical trial by Nam Doo-hyun 2017-12-11 15:50
ToolGen’s shares jump on gene therapy market expectations by Nam Doo-hyun 2017-12-11 15:16
MGmed to run world’s 1st postmortem DNA bank by Marian Chu 2017-12-08 17:11
Toolgen wins German utility model for gene editing tool by Lee Han-soo 2017-12-08 16:56
여백
여백
여백
Back to Top